BMJ Best Practice

参考文献

关键文献

Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis: a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115:341-384.

Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380-384.

Simons FE, Ardusso LR, Bilò MB, et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol. 2012;12:389-399.

National Institute for Health and Care Excellence. Anaphylaxis: assessment and referral after emergency treatment. December 2011. http://www.nice.org.uk/ (last accessed 18 August 2017).

Dinakar, C. Anaphylaxis in children: Current understanding and key issues in diagnosis and treatment. Curr Allergy Asthma Rep. 2012;12:641-649.

Sheikh A, Shehata YA, Brown SG, et al. Adrenaline for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2009;64:204-212.

Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;(10):CD008838.

Wang J, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Allergy Asthma Immunol Res. 2009;1:19-29.

参考文章

1.  Lieberman P, Kemp SF, Oppenheimer J, et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(3 Suppl 2):S483-S523.

2.  Sampson HA, Muñoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2005;115:584-591.

3.  Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391-397.

4.  Moneret-Vautrin DA, Morisset M, Flabbee J, et al. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy. 2005;60:443-451.

5.  Campbell RL, Hagan JB, Manivannan V, et al. Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol. 2012;129:748-752.

6.  Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis: a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115:341-384.

7.  Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001;161:15-21.

8.  Lieberman P, Camargo CA Jr, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97:596-602.

9.  Umasunthar T, Leonardi-Bee J, Turner PJ, et al. Incidence of food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1621-1636.

10.  Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-193.

11.  Smit DV, Cameron PA, Rainer TH. Anaphylaxis presentations to an emergency department in Hong Kong: incidence and predictors of biphasic reactions. J Emerg Med. 2005;28:381-388.

12.  Brown AF, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol. 2001;108:861-866.

13.  Castells MC, Horan RF, Sheffer AL. Exercise-induced anaphylaxis. Curr Allergy Asthma Rep. 2003;3:15-21.

14.  Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380-384.

15.  Sampson HA. Anaphylaxis and emergency treatment. Pediatrics. 2003;111 Suppl 3:1601-1608.

16.  Valentine MD. Anaphylaxis and stinging insect hypersensitivity. JAMA. 1992;268:2830-2833.

17.  Sue MA, Noritake DT, Klaustermeyer WB. Penicillin anaphylaxis: fatality in elderly patients without a history of penicillin allergy. Am J Emerg Med. 1998;6:456-458.

18.  Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120:1373-1377.

19.  Kelso JM, Li JT, Nicklas RA, et al. Adverse reactions to vaccines. Ann Allergy Asthma Immunol. 2009;103(4 Suppl 2):S1-S14.

20.  Public Health England. Chapter 8: Vaccine safety and the management of adverse events following immunisation. In: Immunisation against infectious disease: the Green Book. August 2012. http://immunisation.dh.gov.uk/ (last accessed 18 August 2017).

21.  Public Health England. Chapter 19: Influenza. In: Immunisation against infectious disease: the Green Book. August 2015. http://immunisation.dh.gov.uk/ (last accessed 18 August 2017).

22.  Turner PJ, Southern J, Andrews NJ, et al. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. BMJ. 2015;351:h6291.

23.  Kelso JM. Administering influenza vaccine to egg-allergic persons. Expert Rev Vaccines. 2014;13:1049-1057.

24.  Ewan PW, Dugué P, Mirakian R, et al. BSACI guidelines for the investigation of suspected anaphylaxis during general anaesthesia. Clin Exp Allergy. 2010;40:15-31.

25.  Dewachter P, Mouton-Faivre C. Allergic risk during paediatric anaesthesia [in French]. Ann Fr Anesth Reanim. 2010;29:215-226.

26.  Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am. 2007;27:273-293.

27.  De Weck AL, Sanz ML, Gamboa PM, et al. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome: a multicenter study. II. Basophil activation by nonsteroidal anti-inflammatory drugs and its impact on pathogenesis. J Investig Allergol Clin Immunol. 2010;20:39-57.

28.  Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol. 2000;53:273-276.

29.  Verrill L, Bruns R, Luccioli S. Prevalence of self reported food allergy in US adults: 2001, 2006, and 2010. Allergy Asthma Proc. 2015 Oct 8 [Epub ahead of print].

30.  Brown SG, Franks RW, Baldo BA, et al. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. J Allergy Clin Immunol. 2003;111:187-192.

31.  Lee JM, Greenes DS. Biphasic anaphylactic reactions in pediatrics. Pediatrics. 2000;106:762-766.

32.  Macdougall CF, Cant AJ, Colver AF. How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions across the UK and Ireland. Arch Dis Child. 2002;86:236-239.

33.  Ricci G, Gentili A, Di Lorenzo F, et al. Latex allergy in subjects who had undergone multiple surgical procedures for bladder exstrophy: relationship with clinical intervention and atopic diseases. BJU Int. 1999;84:1058-1062.

34.  Toraason M, Sussman G, Biagini R, et al. Latex allergy in the workplace. Toxicol Sci. 2000;58:5-14.

35.  Ellis AK, Day JH. Diagnosis and management of anaphylaxis. CMAJ. 2003;169:307-312.

36.  Simons FE, Ardusso LR, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;7:9.

37.  Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005;95:217-226.

38.  Douglas DM, Sukenick E, Andrade WP, et al. Biphasic systemic anaphylaxis: an inpatient and outpatient study. J Allergy Clin Immunol. 1994;93:977-985.

39.  Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol. 1986;78:76-83.

40.  Vanden Hoek TL, Morrison LJ, Shuster M, et al. 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 12.2: cardiac arrest associated with anaphylaxis. Circulation. 2010;122(suppl 3):S829-861.

41.  Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol. 2005;5:359-364.

42.  Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371-376.

43.  Brown SG, Blackman KE, Stenlake V, et al. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J. 2004;21:149-154.

44.  Simons FE, Ardusso LR, Bilò MB, et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol. 2012;12:389-399.

45.  National Institute for Health and Care Excellence. Anaphylaxis: assessment and referral after emergency treatment. December 2011. http://www.nice.org.uk/ (last accessed 18 August 2017).

46.  Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26:451-463.

47.  Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2-S24.

48.  Kaliner M, Dyer J, Merlin S. Increased urine histamine and contrast media reactions. Invest Radiol. 1984;19:116-118.

49.  Sampson HA, Ho DG. Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol. 1997;100:444-451.

50.  Rentzos G, Lundberg V, Lundqvist C, et al. Use of a basophil activation test as a complementary diagnostic tool in the diagnosis of severe peanut allergy in adults. Clin Transl Allergy. 2015;5:22.

51.  Wang J, Sampson HA. Food anaphylaxis. Clin Exp Allergy. 2007;37:651-660.

52.  Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415-1418.

53.  Lefèbvre PR, Cordonnier M, Baleriaux D, et al. An unusual cause of visual loss: involvement of bilateral lateral geniculate bodies. AJNR Am J Neuroradiol. 2004;25:1544-1548.

54.  Szeinbach SL, Barnes JH, Sullivan TJ, et al. Precision and accuracy of commercial laboratories' ability to classify positive and/or negative allergen-specific IgE results. Ann Allergy Asthma Immunol. 2001;86:373-381.

55.  Williams PB, Barnes JH, Szeinbach SL, et al. Analytic precision and accuracy of commercial immunoassays for specific IgE: establishing a standard. J Allergy Clin Immunol. 2000;105:1221-1230.

56.  Okudaira H, Ito K, Miyamoto T, et al. Evaluation of new system for the detection of IgE antibodies (CAP) in atopic diseases [in Japanese]. Arerugi. 1991;40:544-554.

57.  Oppenheimer J, Nelson HS. Skin testing. Ann Allergy Asthma Immunol. 2006;96(2 Suppl 1):S6-S12.

58.  Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects. J Allergy Clin Immunol. 2007;119:1462-1469.

59.  Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol. 2006;117(suppl 2):S470-S475.

60.  Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol. 2003;112:451-452.

61.  Singletary EM, Charlton NP, Epstein JL, et al; International Liaison Committee on Resuscitation First Aid Task Force. 2015 American Heart Association and American Red Cross guidelines update for first aid. Circulation. 2015;132(18 suppl 2):s574-s589.

62.  Dinakar, C. Anaphylaxis in children: Current understanding and key issues in diagnosis and treatment. Curr Allergy Asthma Rep. 2012;12:641-649.

63.  Sicherer SH, Simons FE. Epinephrine for first-aid management of anaphylaxis. Pediatrics. 2017;139:e20164006.

64.  Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014. J Allergy Clin Immunol. 2015;135:357-367.

65.  Sheikh A, Simons FE, Barbour V, et al. Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community. Cochrane Database Syst Rev. 2012;(8):CD008935.

66.  Sheikh A, Shehata YA, Brown SG, et al. Adrenaline for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2009;64:204-212.

67.  Sheikh A, Shehata YA, Brown-Simon GA, et al. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev. 2008;(4):CD006312.

68.  Pumphrey RS, Stanworth SJ. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy. 1996;26:1364-1370.

69.  Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108:871-873.

70.  Simons FE, Roberts JR, Gu X, et al. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. 1998;101:33-37.

71.  Medicines and Healthcare products Regulatory Agency. Adrenaline auto-injectors: updated advice after European review. August 2017. https://www.gov.uk (last accessed 18 August 2017).

72.  Wang J, Sicherer SH. Guidance on completing a written allergy and anaphylaxis emergency plan. Pediatrics. 2017;139: e20164005.

73.  Sheikh A, Ten Broek V, Brown SG, et al. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2007;62:830-837.

74.  Sheikh A, Ten Broek VM, Brown-Simon GA, et al. H1-antihistamines for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev. 2007:(1):CD006160.

75.  Brown SG. Anaphylaxis: clinical concepts and research priorities. Emerg Med Australas. 2006;18:155-169.

76.  Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest. 1980;66:1072-1080.

77.  Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol. 2000;106:65-71.

78.  Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203-2217.

79.  Durham SR. Tradition and innovation: finding the right balance. J Allergy Clin Immunol. 2007;119:792-795.

80.  Finegold I. Allergen immunotherapy: present and future. Allergy Asthma Proc. 2007;28:44-49.

81.  Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558-562.

82.  Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116:1073-1079.

83.  Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007;120(suppl 3):S25-S85.

84.  Passalacqua G, Guerra L, Pasquali M, et al. Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets. 2006;5:43-51.

85.  Andreae DA, Andreae MH. Should antihistamines be used to treat anaphylaxis? BMJ. 2009;339:b2489.

86.  Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Rev. 2012;(4):CD007596.

87.  Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;(10):CD008838.

88.  Wood RA. Food allergen immunotherapy: current status and prospects for the future. J Allergy Clin Immunol. 2016;137:973-982.

89.  Wang J, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Allergy Asthma Immunol Res. 2009;1:19-29.

90.  Kleine-Tebbe JB, Huttegger IJ, Saloga U, et al. Specific immunotherapy (hyposensitization) for IgE-mediated allergic diseases. Allergologie. 2010;33:3-34.

91.  Mondoulet L, Dioszeghy V, Ligouis M, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40:659-667.

92.  Briner TJ, Kuo MC, Keating KM, et al. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A. 1993;90:7608-7612.

93.  Smith TR, Alexander C, Kay AB, et al. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy. 2004;59:1097-1101.

94.  Tarzi M, Klunker S, Texier C, et al. Induction of interleukin-10 and suppressor of cytokine signaling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006;36:465-474.

95.  Verhoef A, Alexander C, Kay AB, et al. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PloS Med. 2005;2:e78.

96.  Li XM, Srivastava K, Grishin A, et al. Persistent protective effect of heat-killed Escherichia coli producing "engineered", recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol. 2003;112:159-167.

97.  Li XM, Srivastava K, Huleatt JW, et al. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol. 2003;170:3289-3295.

98.  Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 2000;106:124-134.

99.  Chang TW, Wu PC, Hsu CL, et al. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol. 2007;93:63-119.

100.  Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986-993.

101.  Li XM, Srivastava K. Traditional Chinese medicine for the therapy of allergic disorders. Curr Opin Otolaryngol Head Neck Surg. 2006;14:191-196.

102.  Qu C, Srivastava K, Ko J, et al. Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy. 2007;37:846-855.

103.  Arias K, Baig M, Colangelo M, et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol. 2009;124:307-314.

104.  Kastner M, Harada L, Waserman S. Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature. Allergy. 2010;65:435-444.

105.  Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21:442-453.

106.  Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118:28-54.

使用此内容应接受我们的免责声明